COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
13/01/2026
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic [...]
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
13/01/2026
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
13/01/2026
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
13/01/2026
[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at [...]
University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields
13/01/2026
LONG BEACH, Calif. and TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
13/01/2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European [...]
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13/01/2026
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying [...]
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
13/01/2026
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate [...]
Fedora Pharmaceuticals has Re-emerged to Unveil Novel Class of Antibiotics at 2026 Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
13/01/2026
Edmonton, Alberta, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, announced plans to unveil the company’s lead candidate at [...]
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
13/01/2026
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms [...]
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
13/01/2026
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide [...]
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
13/01/2026
TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based [...]
Dentsply Sirona Appoints Donald Zurbay to Board of Directors
13/01/2026
Company’s Board of Directors forms Growth and Value Creation Committee to guide the Company’s Return-to-Growth Action Plan CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or [...]
Konica Minolta Healthcare and deepc Partner to Bring AI to the Exa Platform
13/01/2026
The companies have a shared vision to make medical imaging AI simpler, faster and more human MUNICH and WAYNE, N.J., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Radiology is under pressure. Imaging volumes continue to rise while [...]
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
13/01/2026
Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical [...]
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
13/01/2026
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
13/01/2026
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Evaxion expands AI-Immunology™ platform into autoimmune diseases
13/01/2026
Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus In future, Evaxion’s proprietary AI-Immunology™ platform will enable the discovery and development of drug candidates targeting [...]
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
13/01/2026
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its [...]

Pages